Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2023

15.03.2023 | Review Article

Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)

verfasst von: Tala B. Shahin, Shreya A. Sreekantaswamy, Jason E. Hawkes, Daniel C. Butler

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Chronic eczematous eruptions of aging (CEEA) refers to a heterogenous group of longstanding, pruritic eczematous dermatoses with an unidentified etiology, or those which do not meet strict disease criteria. The literature has not yet established a single ubiquitous disease or term for these eruptions in adults over the age of 65 years. Instead, CEEA is attributed various names, including immunologic eruption of aging, and eruption of immunosenescence. Atopic dermatitis in the elderly, eczema in the elderly, and late- or adult-onset atopic dermatitis or eczema likely also fall under the umbrella of CEEA, given that older patients often do not meet strict criteria for atopic dermatitis. As a reflection of such terminological heterogeneity, CEEA does not have a standardized workup algorithm. This lack of uniformity can obscure the ability to study and understand appropriate treatments for this condition. Yet, as providers become increasingly aware of CEEA and more comfortable in making this diagnosis in older adults, it is necessary that dermatologists understand the safety and efficacy of common CEEA treatments in this population. Here, we discuss special considerations, challenges, and recommendations for treating older adults with CEEA with topical and systemic therapeutics. We provide an overview of therapeutic strategies and potential barriers to treatment and discuss the essential role of shared decision making when caring for this patient population.
Literatur
1.
Zurück zum Zitat Morin C, Joly P, Courville P, Young P, Richard C, Balguerie X, et al. Chronic eczematiform eruption in the elderly. Ann Dermatol Venereol. 2002;2002:19–22. Morin C, Joly P, Courville P, Young P, Richard C, Balguerie X, et al. Chronic eczematiform eruption in the elderly. Ann Dermatol Venereol. 2002;2002:19–22.
2.
Zurück zum Zitat Joly P, Benoit-Corven C, Lambert A, Hellot M, Josset V, Barbaud A, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case–control study. J Invest Dermatol. 2007;127(12):2766–71.PubMedCrossRef Joly P, Benoit-Corven C, Lambert A, Hellot M, Josset V, Barbaud A, et al. Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case–control study. J Invest Dermatol. 2007;127(12):2766–71.PubMedCrossRef
3.
Zurück zum Zitat Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149(7):814–8.PubMedCrossRef Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149(7):814–8.PubMedCrossRef
4.
Zurück zum Zitat Abel MK, Jelousi S, Berger T, Murase JE, Butler DC. Immunological eruptions of ageing: reframing chronic pruritic rashes in older adults. Br J Dermatol. 2021;185(3):638–9.PubMedCrossRef Abel MK, Jelousi S, Berger T, Murase JE, Butler DC. Immunological eruptions of ageing: reframing chronic pruritic rashes in older adults. Br J Dermatol. 2021;185(3):638–9.PubMedCrossRef
8.
Zurück zum Zitat Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-32.e7.PubMedCrossRef Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526-32.e7.PubMedCrossRef
10.
Zurück zum Zitat Beckman AGK, Parker MG, Thorslund M. Can elderly people take their medicine? Patient Educ Couns. 2005;59(2):186–91.PubMedCrossRef Beckman AGK, Parker MG, Thorslund M. Can elderly people take their medicine? Patient Educ Couns. 2005;59(2):186–91.PubMedCrossRef
11.
Zurück zum Zitat Lisberg R,Higham C, Jayson M. Problems for rheumatic patients in opening dispensed drug containers. Br J Rheumatol. 1983;22(2):95–8. Lisberg R,Higham C, Jayson M. Problems for rheumatic patients in opening dispensed drug containers. Br J Rheumatol. 1983;22(2):95–8.
12.
Zurück zum Zitat Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033–47.PubMedCrossRef Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033–47.PubMedCrossRef
13.
Zurück zum Zitat Joray S, Wietlisbach V, Büla C. Cognitive impairment in elderly medical inpatients: detection and associated six-month outcomes. Am J Geriatr Psychiatry. 2004;12(6):639–47.PubMed Joray S, Wietlisbach V, Büla C. Cognitive impairment in elderly medical inpatients: detection and associated six-month outcomes. Am J Geriatr Psychiatry. 2004;12(6):639–47.PubMed
14.
Zurück zum Zitat Wilson IB, Schoen C, Neuman P, Strollo MK, Rogers WH, Chang H, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniors. J Gen Intern Med. 2007;22(1):6–12.PubMedPubMedCentralCrossRef Wilson IB, Schoen C, Neuman P, Strollo MK, Rogers WH, Chang H, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America’s seniors. J Gen Intern Med. 2007;22(1):6–12.PubMedPubMedCentralCrossRef
15.
16.
Zurück zum Zitat Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.PubMedCrossRef Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.PubMedCrossRef
17.
Zurück zum Zitat Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef
18.
Zurück zum Zitat Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff. 2003;22(4):220–9.CrossRef Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff. 2003;22(4):220–9.CrossRef
19.
Zurück zum Zitat Farage MA, Miller KW, Sherman SN, Tsevat J. Assessing quality of life in older adult patients with skin disorders. Glob J Health Sci. 2012;4(2):119–31.PubMedPubMedCentralCrossRef Farage MA, Miller KW, Sherman SN, Tsevat J. Assessing quality of life in older adult patients with skin disorders. Glob J Health Sci. 2012;4(2):119–31.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.PubMedCrossRef Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.PubMedCrossRef
21.
Zurück zum Zitat Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.PubMedCrossRef Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.PubMedCrossRef
22.
Zurück zum Zitat Pieterse AH, Finset A. Shared decision making—much studied, much still unknown. Patient Educ Couns. 2019;102(11):1946–8.PubMedCrossRef Pieterse AH, Finset A. Shared decision making—much studied, much still unknown. Patient Educ Couns. 2019;102(11):1946–8.PubMedCrossRef
23.
Zurück zum Zitat Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25(1):12–8.PubMedCrossRef Katsarou A, Armenaka MC. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25(1):12–8.PubMedCrossRef
24.
Zurück zum Zitat Lima AL, Timmermann V, Illing T, Elsner P. Contact dermatitis in the elderly: predisposing factors, diagnosis, and management. Drugs Aging. 2019;36(5):411–7.PubMedCrossRef Lima AL, Timmermann V, Illing T, Elsner P. Contact dermatitis in the elderly: predisposing factors, diagnosis, and management. Drugs Aging. 2019;36(5):411–7.PubMedCrossRef
25.
Zurück zum Zitat Zirwas MJ, Barkovic S. Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream. J Drugs Dermatol. 2017;16(3):243–7.PubMed Zirwas MJ, Barkovic S. Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream. J Drugs Dermatol. 2017;16(3):243–7.PubMed
26.
Zurück zum Zitat Fowler JF, Nebus J, Wallo W, Eichenfield L. Colloidal oatmeal formulations as adjunct treatments in atopic dermatitis. J Drugs Dermatol. 2012;11(7):804–7.PubMed Fowler JF, Nebus J, Wallo W, Eichenfield L. Colloidal oatmeal formulations as adjunct treatments in atopic dermatitis. J Drugs Dermatol. 2012;11(7):804–7.PubMed
27.
Zurück zum Zitat Katoh N, Tennstedt D, Abellan van Kan G, Saint Aroman M, Loir A, Bacqueville D, et al. Gerontodermatology: the fragility of the epidermis in older adults. Journal of the European Academy of Dermatology and Venereology. 2018;32(S4):1–20. Katoh N, Tennstedt D, Abellan van Kan G, Saint Aroman M, Loir A, Bacqueville D, et al. Gerontodermatology: the fragility of the epidermis in older adults. Journal of the European Academy of Dermatology and Venereology. 2018;32(S4):1–20.
28.
29.
Zurück zum Zitat Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Investig Dermatol. 1988;90(4):532–5.PubMedCrossRef Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Investig Dermatol. 1988;90(4):532–5.PubMedCrossRef
30.
Zurück zum Zitat May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med. 1976;136(5):612–3.PubMedCrossRef May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med. 1976;136(5):612–3.PubMedCrossRef
31.
Zurück zum Zitat Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol. 1976;112(11):1559–62.PubMedCrossRef Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol. 1976;112(11):1559–62.PubMedCrossRef
35.
Zurück zum Zitat Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82.PubMedCrossRef Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–82.PubMedCrossRef
36.
Zurück zum Zitat Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163(1):70–7.PubMedCrossRef Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163(1):70–7.PubMedCrossRef
37.
Zurück zum Zitat Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. JAAD. 2014;71(1):116–32. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. JAAD. 2014;71(1):116–32.
38.
Zurück zum Zitat Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Investig Dermatol. 1996;107(1):51–6.PubMedCrossRef Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Investig Dermatol. 1996;107(1):51–6.PubMedCrossRef
39.
Zurück zum Zitat Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274–89.PubMedCrossRef Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274–89.PubMedCrossRef
41.
Zurück zum Zitat Labib A, Does AV, Korbutov J, Yosipovitch G. Silicone barrier cream in treatment of atopic dermatitis: a literature review. Dermatol Ther. 2022;35(12): e15884.PubMedCrossRef Labib A, Does AV, Korbutov J, Yosipovitch G. Silicone barrier cream in treatment of atopic dermatitis: a literature review. Dermatol Ther. 2022;35(12): e15884.PubMedCrossRef
42.
Zurück zum Zitat Panther DJ, Jacob SE. The importance of acidification in atopic eczema: an underexplored avenue for treatment. J Clin Med. 2015;18(4):970–8.CrossRef Panther DJ, Jacob SE. The importance of acidification in atopic eczema: an underexplored avenue for treatment. J Clin Med. 2015;18(4):970–8.CrossRef
43.
Zurück zum Zitat Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23.PubMedCrossRef Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23.PubMedCrossRef
44.
Zurück zum Zitat Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol. 1995;154(9):4851.PubMedCrossRef Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol. 1995;154(9):4851.PubMedCrossRef
45.
47.
Zurück zum Zitat Gloor M, Scherotzke A. Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure. Photodermatol Photoimmunol Photomed. 2002;18(3):121–6.PubMedCrossRef Gloor M, Scherotzke A. Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure. Photodermatol Photoimmunol Photomed. 2002;18(3):121–6.PubMedCrossRef
48.
Zurück zum Zitat Yaar M, Gilchrest BA. Ageing and photoageing of keratinocytes and melanocytes. Clin Exp Dermatol. 2001;26(7):583–91.PubMedCrossRef Yaar M, Gilchrest BA. Ageing and photoageing of keratinocytes and melanocytes. Clin Exp Dermatol. 2001;26(7):583–91.PubMedCrossRef
50.
Zurück zum Zitat Dennis M, Bhutani T, Koo J, Liao W. Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. J Dermatol Treat. 2013;24(1):2–6.CrossRef Dennis M, Bhutani T, Koo J, Liao W. Goeckerman therapy for the treatment of eczema: a practical guide and review of efficacy. J Dermatol Treat. 2013;24(1):2–6.CrossRef
51.
Zurück zum Zitat Storan ER, McEvoy MT, Wetter DA, El-Azhary RA, Bridges AG, Camilleri MJ, et al. Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic. Int J Dermatol. 2015;54(5):600–4.PubMedCrossRef Storan ER, McEvoy MT, Wetter DA, El-Azhary RA, Bridges AG, Camilleri MJ, et al. Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic. Int J Dermatol. 2015;54(5):600–4.PubMedCrossRef
54.
Zurück zum Zitat Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J. 2008;10(6):413–4.PubMed Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J. 2008;10(6):413–4.PubMed
55.
Zurück zum Zitat Nedelcu R-I, Balaban M, Turcu G, Brinzea A, Ion DA, Antohe M, et al. Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: three case reports. Exp Ther Med. 2019;18(2):905–10.PubMedPubMedCentral Nedelcu R-I, Balaban M, Turcu G, Brinzea A, Ion DA, Antohe M, et al. Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: three case reports. Exp Ther Med. 2019;18(2):905–10.PubMedPubMedCentral
56.
Zurück zum Zitat Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. JAAD. 2014;71(2):327–49. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. JAAD. 2014;71(2):327–49.
57.
Zurück zum Zitat Paul MA, Jorizzo JL, Fleischer AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. JAAD. 1994;31(4):620–5.PubMedCrossRef Paul MA, Jorizzo JL, Fleischer AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. JAAD. 1994;31(4):620–5.PubMedCrossRef
58.
Zurück zum Zitat Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J. 2000;76(902):787.PubMedPubMedCentralCrossRef Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J. 2000;76(902):787.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, et al. INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. J Clin Exp Hepatol. 2018;8(4):403–31.PubMedPubMedCentralCrossRef Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, et al. INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids. J Clin Exp Hepatol. 2018;8(4):403–31.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3.PubMedCrossRef Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3.PubMedCrossRef
64.
Zurück zum Zitat Marcum ZA, Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. Ann Longterm Care. 2010;18(9):24–7.PubMedPubMedCentral Marcum ZA, Hanlon JT. Recognizing the risks of chronic nonsteroidal anti-inflammatory drug use in older adults. Ann Longterm Care. 2010;18(9):24–7.PubMedPubMedCentral
65.
Zurück zum Zitat American Geriatrics Society. 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. American Geriatrics Society. 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.
66.
Zurück zum Zitat Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentralCrossRef Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.PubMedCrossRef Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.PubMedCrossRef
68.
Zurück zum Zitat Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. JAAD. 2017;76(1):1–9.PubMedCrossRef Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health. JAAD. 2017;76(1):1–9.PubMedCrossRef
69.
Zurück zum Zitat Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):e232.CrossRef Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):e232.CrossRef
73.
Zurück zum Zitat Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedCrossRef Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.PubMedCrossRef
74.
Zurück zum Zitat Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.PubMedPubMedCentralCrossRef Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Dharmasiri S, Johnson H, McLaughlin S, Weaver S. PTU-109 azathioprine in the elderly—is it tolerated and is it safe? Gut. 2014;63(Suppl 1):A87.CrossRef Dharmasiri S, Johnson H, McLaughlin S, Weaver S. PTU-109 azathioprine in the elderly—is it tolerated and is it safe? Gut. 2014;63(Suppl 1):A87.CrossRef
78.
Zurück zum Zitat Baghoomian W, Na C, Simpson EL. New and emerging biologics for atopic dermatitis. Am J Clin Dermatol. 2020;21(4):457–65.PubMedCrossRef Baghoomian W, Na C, Simpson EL. New and emerging biologics for atopic dermatitis. Am J Clin Dermatol. 2020;21(4):457–65.PubMedCrossRef
80.
Zurück zum Zitat Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020;45(7):888–90.PubMedCrossRef Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020;45(7):888–90.PubMedCrossRef
81.
Zurück zum Zitat Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–6.PubMedCrossRef Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol. 2021;22(4):581–6.PubMedCrossRef
82.
Zurück zum Zitat He H, Guttman-Yassky E. JAK Inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–92.PubMedCrossRef He H, Guttman-Yassky E. JAK Inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–92.PubMedCrossRef
83.
Zurück zum Zitat Pfizer Labs. Cibinqo (abrocitinib) [package insert]. 2022 [cited 2023 January 1]. Pfizer Labs. Cibinqo (abrocitinib) [package insert]. 2022 [cited 2023 January 1].
84.
Zurück zum Zitat Abbvie Inc. Rinvoq (upadacitinib) [package insert]. 2022 [cited 2023 January 1]. Abbvie Inc. Rinvoq (upadacitinib) [package insert]. 2022 [cited 2023 January 1].
87.
Zurück zum Zitat Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus Kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9.PubMedPubMedCentralCrossRef Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus Kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9.PubMedPubMedCentralCrossRef
88.
Zurück zum Zitat Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA). 2021. Pfizer. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA). 2021.
89.
Zurück zum Zitat Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–62.PubMedCrossRef Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953–62.PubMedCrossRef
92.
Zurück zum Zitat Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol. 2020;156(11):1240–5.PubMedCrossRef Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol. 2020;156(11):1240–5.PubMedCrossRef
93.
Zurück zum Zitat Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86.PubMedCrossRef Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86.PubMedCrossRef
Metadaten
Titel
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)
verfasst von
Tala B. Shahin
Shreya A. Sreekantaswamy
Jason E. Hawkes
Daniel C. Butler
Publikationsdatum
15.03.2023
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2023
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-023-00767-7

Weitere Artikel der Ausgabe 3/2023

American Journal of Clinical Dermatology 3/2023 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.